Questions discussed in this category
What is your evaluation approach for RAI response? What cumulative dose do you use in practice for deciding a patient is RAI refractory?
What techniques and doses would you prescribe to the primary and regional nodes?
Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?
Patient does not have hypercalcemia.
2156520370202841994519223803018835155218963
Papers discussed in this category
Cancer discovery, 2015-07
J Immunother Cancer,
Thyroid : official journal of the American Thyroid Association, 2020 May 07
Journal of thyroid research, 2020 Apr 14